NASDAQ:ACTU Actuate Therapeutics (ACTU) Stock Price, News & Analysis $0.45 -0.02 (-4.14%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Actuate Therapeutics Stock (NASDAQ:ACTU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Actuate Therapeutics alerts:Sign Up Key Stats Today's Range$0.41▼$0.4950-Day Range$0.47▼$1.7852-Week Range$0.41▼$8.20Volume333,451 shsAverage Volume221,600 shsMarket Capitalization$10.73 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingHold Company Overview Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s research centers on glycogen synthase kinase-3 beta (GSK-3β), a signaling protein involved in tumor growth, inflammation and immune regulation. Actuate’s lead investigational product is elraglusib, also known as 9-ING-41, a selective small-molecule inhibitor of GSK-3β. The company has studied elraglusib in clinical programs involving hematologic malignancies and solid tumors, including acute myeloid leukemia, myelodysplastic syndromes, neuroblastoma and pancreatic cancer. Elraglusib remains an investigational therapy and has not been approved for general commercial use. Actuate is headquartered in Houston, Texas, and conducts development activities through clinical research programs and collaborations with academic and medical institutions. Publicly available information identifies Anwaar Saeed, M.D., as a senior leader associated with the company’s clinical and executive operations.AI Generated. May Contain Errors. Read More Actuate Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreACTU MarketRank™: 2.20945502298 of 5 starsActuate Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 643rd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingActuate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialActuate Therapeutics has a consensus price target of $10.50, representing about 2,238.5% upside from its current price of $0.45.Amount of Analyst CoverageActuate Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Actuate Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actuate Therapeutics are expected to grow in the coming year, from ($0.73) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actuate Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actuate Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActuate Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.18% of the float of Actuate Therapeutics has been sold short.Short Interest Ratio / Days to CoverActuate Therapeutics has a short interest ratio ("days to cover") of 5.61.Change versus previous monthShort interest in Actuate Therapeutics has recently increased by 21.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActuate Therapeutics does not currently pay a dividend.Dividend GrowthActuate Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.61 News SentimentActuate Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Actuate Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for ACTU on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actuate Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders57.98% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsActuate Therapeutics has minimal institutional ownership at this time.Read more about Actuate Therapeutics' insider trading history. Receive ACTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACTU Stock News HeadlinesActuate Therapeutics (NASDAQ:ACTU) Stock Falls 6.2% - Here's WhyOctober 9, 2026 | americanbankingnews.comActuate Therapeutics' Stock Tumble on Plan to Sell 50M SharesOctober 6, 2026 | marketwatch.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Actuate Therapeutics consensus price target decreased by 33.33% to $11.90September 15, 2026 | msn.comActuate to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | globenewswire.comActuate Therapeutics: Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and DaraxonrasibSeptember 9, 2026 | finanznachrichten.deActuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and DaraxonrasibSeptember 9, 2026 | globenewswire.comActuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric NeuroblastomaJune 9, 2026 | markets.businessinsider.comSee More Headlines ACTU Stock Analysis - Frequently Asked Questions How have ACTU shares performed this year? Actuate Therapeutics' stock was trading at $6.12 at the beginning of 2026. Since then, ACTU stock has decreased by 92.7% and is now trading at $0.4490. How were Actuate Therapeutics' earnings last quarter? Actuate Therapeutics, Inc. (NASDAQ:ACTU) announced its quarterly earnings results on Friday, August, 14th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. When did Actuate Therapeutics IPO? Actuate Therapeutics (ACTU) raised $27 million in an initial public offering on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager. How do I buy shares of Actuate Therapeutics? Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today10/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ACTU's financial health is in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ACTU Previous SymbolNASDAQ:ACTU CIK1652935 Webactuatetherapeutics.com Phone(847) 986-4190FaxN/AEmployees12Year Founded2015Price Target and Rating Average Price Target for Actuate Therapeutics$10.50 High Price Target$15.00 Low Price Target$6.00 Potential Upside/Downside+2,254.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-346.19% Return on Assets-178.40% Debt Debt-to-Equity RatioN/A Current Ratio1.25 Quick Ratio1.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book1.31Miscellaneous Outstanding Shares24,010,000Free Float10,091,000Market Cap$10.71 million OptionableN/A Beta1.20 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ACTU) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
